Skip to main content
Caplight Logo









Brink Therapeutics

Brink Therapeutics

Private
ParisHealthcare & Life Scienceshttps://www.brinktx.com/

Last Round

Seed

Apr 16, 2025

Total Funding Raised

$3.99M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Brink Therapeutics is a biotechnology company developing a gene-editing platform centered on the discovery and development of therapeutic recombinases for cell and gene therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Infrastructure

Keywords

gene editing platformprogrammable integrasesnuclease-free gene editingCRISPR alternativelarge payload gene therapygenerative AI protein designcell and gene therapygenomic integrationCAR-T cell therapyAI drug discoveryin vivo gene therapygenerative biologydirected evolutionmonogenic rare diseaseshigh-throughput screeningplatform licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Brink Therapeutics Comparables

Compare Brink Therapeutics with similar companies based on industry and business-model similarity.

Brink Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Seamless Therapeutics
85%
IntegraTherapeutics
81%
Komo Biosciences
81%

Brink Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedApr 16, 2025

Key People

Founding team and executive leadership

Harry Kemble

CTO & Co-Founder

Founding Team

Jonathan Naccache

CEO & Co-founder

Founding Team

Brink Therapeutics Investors

Notable investors and investment history

Brink Therapeutics investors
InvestorRounds
Kima VenturesSeed
Plug and Play Tech CenterSeed
BreegaSeed
Kurma PartnersSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 139% MoM, reaching 2.9K.

  • Apr 17, 2026

    Grew 38% QoQ, from 8 to 11 employees.

Brink Therapeutics Filings

Explore SEC and related filing metadata, where available.

Brink Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Brink Therapeutics's valuation, stock price, and market status.

Is Brink Therapeutics a public or private company?

Brink Therapeutics is a private company.

What is the current stock price of Brink Therapeutics?

Brink Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Brink Therapeutics worth (valuation)?

Valuation information for Brink Therapeutics is not publicly available.

Can I buy Brink Therapeutics stock?

Brink Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Brink Therapeutics's last funding round?

Brink Therapeutics's most recent funding round was Seed on April 16, 2025.

Who are the main investors in Brink Therapeutics?

Key investors in Brink Therapeutics include Breega, Kurma Partners.

Will Brink Therapeutics IPO soon?

No public IPO plans have been announced for Brink Therapeutics.

How can I track Brink Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Brink Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersParis
Employee Range11
Year Founded2024
Last FundingApr 16, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?